Jukka Westermarck

11.6k total citations · 4 hit papers
116 papers, 8.8k citations indexed

About

Jukka Westermarck is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Jukka Westermarck has authored 116 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Molecular Biology, 40 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Jukka Westermarck's work include Cancer-related Molecular Pathways (18 papers), Ubiquitin and proteasome pathways (16 papers) and Histone Deacetylase Inhibitors Research (9 papers). Jukka Westermarck is often cited by papers focused on Cancer-related Molecular Pathways (18 papers), Ubiquitin and proteasome pathways (16 papers) and Histone Deacetylase Inhibitors Research (9 papers). Jukka Westermarck collaborates with scholars based in Finland, United States and Canada. Jukka Westermarck's co-authors include Veli‐Matti Kähäri, Melissa R. Junttila, William C. Hahn, Amanpreet Kaur, Johanna Ivaska, Daniel Abankwa, Camilo Guzmán, Jyrki Heino, Leeni Koivisto and Tuula Kallunki and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jukka Westermarck

114 papers receiving 8.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regulation of matrix metalloproteinase expression in tumor invasion

1999 1.3k citations Jukka Westermarck, Veli‐Matti Kähäri profile →
Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

2007 684 citations Melissa R. Junttila, Jukka Westermarck et al. profile →
CIP2A Inhibits PP2A in Human Malignancies

2007 533 citations Melissa R. Junttila, Pietri Puustinen et al. Cell profile →
ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays

2014 469 citations Amanpreet Kaur, Jukka Westermarck et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jukka Westermarck Finland	45	5.5k	2.4k	2.3k	921	752	116	8.8k
József Tı́már Hungary	50	4.0k 0.7×	3.2k 1.3×	1.9k 0.8×	909 1.0×	965 1.3×	328	8.4k
Anna Dimberg Sweden	38	4.5k 0.8×	2.2k 0.9×	1.5k 0.7×	630 0.7×	471 0.6×	92	7.8k
Rakesh Kumar United States	64	7.5k 1.4×	3.7k 1.5×	1.9k 0.8×	1.2k 1.3×	649 0.9×	295	11.5k
Sylvain Meloche Canada	54	7.3k 1.3×	1.9k 0.8×	1.3k 0.6×	1.1k 1.2×	352 0.5×	151	10.6k
Raffaella Giavazzi Italy	57	6.2k 1.1×	4.0k 1.6×	3.4k 1.5×	1.0k 1.1×	1.3k 1.8×	232	11.4k
Dieter Marmé Germany	58	8.1k 1.5×	2.1k 0.8×	2.1k 0.9×	891 1.0×	603 0.8×	140	11.4k
Erik Bruyneel Belgium	47	4.7k 0.8×	2.2k 0.9×	1.3k 0.6×	1.3k 1.4×	685 0.9×	123	7.3k
Tiebang Kang China	51	6.3k 1.1×	2.4k 1.0×	3.4k 1.5×	538 0.6×	245 0.3×	156	8.9k
Karl R. Clauser United States	49	7.2k 1.3×	2.2k 0.9×	1.1k 0.5×	1.5k 1.6×	507 0.7×	84	11.6k
Norbert Kraut Austria	33	5.0k 0.9×	2.7k 1.1×	1.4k 0.6×	1.7k 1.9×	272 0.4×	72	7.2k

Countries citing papers authored by Jukka Westermarck

Since Specialization

Citations

This map shows the geographic impact of Jukka Westermarck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jukka Westermarck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jukka Westermarck more than expected).

Fields of papers citing papers by Jukka Westermarck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jukka Westermarck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jukka Westermarck. The network helps show where Jukka Westermarck may publish in the future.

Co-authorship network of co-authors of Jukka Westermarck

This figure shows the co-authorship network connecting the top 25 collaborators of Jukka Westermarck. A scholar is included among the top collaborators of Jukka Westermarck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jukka Westermarck. Jukka Westermarck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Wei, J. Lang, Chun Wai Wong, et al.. (2025). NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition. Oncogene. 44(33). 2929–2941.

Vogt, Andreas, Ilkka Paatero, Klaus Elenius, et al.. (2024). DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Molecular Medicine. 16(7). 1603–1629. 9 indexed citations

Westermarck, Jukka, et al.. (2023). CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response. Trends in cancer. 10(1). 52–64. 11 indexed citations

Aakula, Anna, Francesco Tabaro, Matthieu Schapira, et al.. (2023). RAS and PP2A activities converge on epigenetic gene regulation. Life Science Alliance. 6(5). e202301928–e202301928. 7 indexed citations

Westermarck, Jukka. (2023). Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?. Molecular Oncology. 17(4). 537–540. 9 indexed citations

Pouwels, Jeroen, et al.. (2022). SHARPIN S146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis. Journal of Cell Science. 135(20). 3 indexed citations

Cvrljevic, Anna N., Kaisa Huhtinen, Tove J. Grönroos, et al.. (2022). Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype. Molecular Cancer Therapeutics. 21(7). 1236–1245. 3 indexed citations

Prabhakar, Neeraj, Vadim Le Joncour, Markus Peurla, et al.. (2021). Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions. Cancers. 13(11). 2631–2631. 11 indexed citations

Pavic, Karolina, Urpu Salmenniemi, Eliisa Löyttyniemi, et al.. (2021). Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. Clinical Cancer Research. 27(10). 2848–2860. 12 indexed citations

10.

Liu, Ying, Maria Llamazares Prada, Abhishekh Gupta, et al.. (2020). UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis. Cancer Research. 80(7). 1414–1427. 31 indexed citations

11.

Ullah, Ubaid, Lingjia Kong, Robert Moulder, et al.. (2020). CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling. iScience. 23(3). 100947–100947. 11 indexed citations

12.

O’Connor, Caitlin M., Daniel Léonard, Danica Wiredja, et al.. (2019). Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene. 39(3). 703–717. 27 indexed citations

13.

Kauko, Otto & Jukka Westermarck. (2018). Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer. The International Journal of Biochemistry & Cell Biology. 96. 157–164. 79 indexed citations

14.

Sents, Ward, Bob Meeusen, Enrico Radaelli, et al.. (2017). PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development. Cancer Research. 77(24). 6825–6837. 31 indexed citations

15.

Kaur, Amanpreet, Oxana V. Denisova, Emilia Peuhu, et al.. (2016). PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. Cancer Research. 76(23). 7001–7011. 38 indexed citations

16.

Laine, Anni, Harri Sihto, Christophé Côme, et al.. (2013). Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1. Cancer Discovery. 3(2). 182–197. 101 indexed citations

17.

Côme, Christophé, Anni Laine, Maïa Chanrion, et al.. (2009). CIP2A Is Associated with Human Breast Cancer Aggressivity. Clinical Cancer Research. 15(16). 5092–5100. 185 indexed citations

18.

Puustinen, Pietri, Melissa R. Junttila, Sari Vanhatupa, et al.. (2009). PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant Glioma. Cancer Research. 69(7). 2870–2877. 81 indexed citations

19.

Junttila, Melissa R., Pietri Puustinen, Minna Niemelä, et al.. (2007). CIP2A Inhibits PP2A in Human Malignancies. Cell. 130(1). 51–62. 533 indexed citations breakdown →

20.

Westermarck, Jukka, Song-Ping Li, Tuula Kallunki, Jiahuai Han, & Veli‐Matti Kähäri. (2001). p38 Mitogen-Activated Protein Kinase-Dependent Activation of Protein Phosphatases 1 and 2A Inhibits MEK1 and MEK2 Activity and Collagenase 1 (MMP-1) Gene Expression. Molecular and Cellular Biology. 21(7). 2373–2383. 178 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact